4 companies · 2 sourced backers · 26 milestones on record
Bioprinting and lab-grown tissue aim to create human tissue for drug testing and, ultimately, transplantable organs. Companies are working to identify harmful drug effects with less reliance on animal testing, build tissue with working blood vessels, and expand organ supply. The bioprinting work described remains research rather than established organ transplantation.
Where the 4 companies stand today, from their profiles and 10-year milestones. Tap a phase to see who is there.
- ▸Making printed tissue function, not just resemble tissue shapes
- ▸Creating working blood vessel structures
- ▸Establishing organ safety and effectiveness for transplantation
- ▸Making human tissue models useful for identifying harmful drug effects
Publicly listed: 3 companies (owned by public shareholders).
- ›Every sourced story on all frontiers, filterable by company and news type
- ›10-year milestone records for each company: demo vs shipped
- ›Explained: plain-words readiness diagrams for real breakthroughs
- ›Signal Trends of 39 frontiers covering 378 companies over time.
- ›The events calendar: launches, approvals and deadlines ahead
- 3D Systems (Bioprinting)
The long-term goal is to bioprint functional, vascularised human tissue and ultimately transplantable organs.
Trials · publicly listed
- Prellis Biologics
To produce useful human tissue with working vessel structures through high-resolution bioprinting.
Some users · backed by Khosla Ventures, SOSV
- United Therapeutics
To expand the supply of transplantable organs through manufacturing and animal-to-human transplantation technologies.
Everyone · publicly listed
- VivoSim Labs (formerly Organovo)
To make bioprinted human tissue a useful way to test drug safety before treatment reaches patients.
Trials · publicly listed
Keep following breakthroughs like these. Every Monday, get up to 5 major breakthroughs and launches explained in plain English.
Free. No account needed. One email a week. Unsubscribe anytime.